TMCI
Treace Medical Concepts, Inc.
Price Chart
Latest Quote
$4.17
+0.17 (+4.11%)
Current Price
| Previous Close | $4.01 |
| Open | $4.13 |
| Day High | $4.37 |
| Day Low | $4.05 |
| Volume | 554,056 |
Stock Information
| Shares Outstanding | 64.87M |
| Total Debt | $71.60M |
| Cash Equivalents | $51.85M |
| Revenue | $207.32M |
| Net Income | $-61.04M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $270.84M |
| EPS (TTM) | $-0.96 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $287.03M |
| Sales | $207.32M |
| Income | $-61.04M |
| Book/sh | $1.19 |
| Cash/sh | $0.80 |
| Employees | 450 |
Financial Ratios
| Quick Ratio | 2.40 |
| Current Ratio | 3.58 |
| Debt/Eq | 92.76 |
Returns & Margins
| ROA | -17.87% |
| ROE | -66.88% |
| Gross Margin | 79.72% |
| Operating Margin | -36.37% |
| Profit Margin | -29.44% |
Ownership
| Insider Ownership | 25.35% |
| Institutional Ownership | 57.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.64 |
| P/S | 1.31 |
| P/B | 3.51 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $3.56 |
| SMA50 | $2.67 |
| SMA200 | $3.40 |
| RSI | 63.67 |
| ATR | 0.3669 |
| Shares Float | 47.29M |
| Short Float | 7.95% |
| Short Ratio | 7.42 |
| Volatility | 1.41 |
| Rel Volume | 0.86 |
Performance History
| Week | +6.78% |
| Month | +53.49% |
| Quarter | +218.70% |
| 6 Months | +54.63% |
| YTD | +67.00% |
| Year | -23.25% |
| 3 Years | -83.60% |
| 5 Years | -88.44% |
| 10 Years | -83.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.18 | 554,056 |
| 2026-06-17 | $4.01 | 852,100 |
| 2026-06-16 | $4.12 | 795,400 |
| 2026-06-15 | $3.92 | 857,000 |
| 2026-06-12 | $4.06 | 1,004,100 |
| 2026-06-11 | $3.91 | 1,299,000 |
| 2026-06-10 | $4.23 | 744,800 |
| 2026-06-09 | $3.73 | 363,900 |
| 2026-06-08 | $3.53 | 380,000 |
| 2026-06-05 | $3.51 | 494,100 |
| 2026-06-04 | $3.69 | 786,800 |
| 2026-06-03 | $3.40 | 606,800 |
| 2026-06-02 | $3.47 | 718,200 |
| 2026-06-01 | $3.60 | 801,100 |
| 2026-05-29 | $3.46 | 810,600 |
| 2026-05-28 | $3.08 | 443,600 |
| 2026-05-27 | $2.90 | 423,800 |
| 2026-05-26 | $2.83 | 391,500 |
| 2026-05-22 | $2.78 | 334,400 |
| 2026-05-21 | $2.84 | 242,100 |
| 2026-05-20 | $2.82 | 635,700 |
| 2026-05-19 | $2.72 | 853,600 |
| 2026-05-18 | $2.75 | 946,200 |
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
đ° Latest News
June 2026's Top Penny Stocks To Watch
Simply Wall St. âĸ 2026-06-11T12:05:40Z
Treace Medical (TMCI) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-06-01T17:35:45Z
Treace Medical (TMCI) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-06-01T17:34:55Z
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
Simply Wall St. âĸ 2026-05-13T12:05:23Z
Treace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...
GuruFocus.com âĸ 2026-05-09T07:02:45ZTreace Medical Concepts Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T04:07:09Z
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-08T12:25:03Z
How The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst Expectations
Simply Wall St. âĸ 2026-05-03T08:06:29Z
How The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product Plans
Simply Wall St. âĸ 2026-04-17T23:07:15Z
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
Simply Wall St. âĸ 2026-04-13T12:05:33Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $42,938,000 | $41,093,000 | $35,181,000 | $25,532,000 |
| Cost Of Revenue | $42,938,000 | $41,093,000 | $35,181,000 | $25,532,000 |
| Total Revenue | $212,690,000 | $209,357,000 | $187,118,000 | $141,838,000 |
| Operating Revenue | $212,690,000 | $209,357,000 | $187,118,000 | $141,838,000 |
| Expenses | ||||
| Interest Expense | $5,320,000 | $5,256,000 | $5,167,000 | $4,398,000 |
| Total Expenses | $266,844,000 | $265,045,000 | $238,546,000 | $176,682,000 |
| Other Income Expense | $-2,305,000 | $324,000 | $342,000 | $-4,886,000 |
| Other Non Operating Income Expenses | $432,000 | $324,000 | $342,000 | $-403,000 |
| Net Non Operating Interest Income Expense | $-2,543,000 | $-379,000 | $1,559,000 | $-3,085,000 |
| Interest Expense Non Operating | $5,320,000 | $5,256,000 | $5,167,000 | $4,398,000 |
| Operating Expense | $223,906,000 | $223,952,000 | $203,365,000 | $151,150,000 |
| Selling And Marketing Expense | $140,880,000 | $147,643,000 | $140,894,000 | $104,567,000 |
| General And Administrative Expense | $62,744,000 | $55,720,000 | $47,031,000 | $32,999,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Net Interest Income | $-2,543,000 | $-379,000 | $1,559,000 | $-3,085,000 |
| Interest Income | $2,777,000 | $4,877,000 | $6,726,000 | $1,313,000 |
| Normalized Income | $-56,265,000 | $-55,743,000 | $-49,527,000 | $-38,332,000 |
| Net Income From Continuing And Discontinued Operation | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Total Operating Income As Reported | $-54,154,000 | $-55,688,000 | $-51,428,000 | $-34,844,000 |
| Net Income Common Stockholders | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Net Income | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Net Income Including Noncontrolling Interests | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Net Income Continuous Operations | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Pretax Income | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Special Income Charges | $-2,737,000 | $0 | $0 | $-4,483,000 |
| Interest Income Non Operating | $2,777,000 | $4,877,000 | $6,726,000 | $1,313,000 |
| Operating Income | $-54,154,000 | $-55,688,000 | $-51,428,000 | $-34,844,000 |
| Gross Profit | $169,752,000 | $168,264,000 | $151,937,000 | $116,306,000 |
| Per Share | ||||
| Diluted EPS | $-0.93 | $-0.90 | $-0.81 | $-0.77 |
| Basic EPS | $-0.93 | $-0.90 | $-0.81 | $-0.77 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-40,322,000 | $-42,068,000 | $-39,008,000 | $-31,801,000 |
| Total Unusual Items | $-2,737,000 | $0 | $0 | $-4,483,000 |
| Total Unusual Items Excluding Goodwill | $-2,737,000 | $0 | $0 | $-4,483,000 |
| Reconciled Depreciation | $10,623,000 | $8,419,000 | $5,352,000 | $2,133,000 |
| EBITDA (Bullshit earnings) | $-43,059,000 | $-42,068,000 | $-39,008,000 | $-36,284,000 |
| EBIT | $-53,682,000 | $-50,487,000 | $-44,360,000 | $-38,417,000 |
| Diluted Average Shares | $63,269,003 | $62,112,037 | $60,852,153 | $55,276,834 |
| Basic Average Shares | $63,269,003 | $62,112,037 | $60,852,153 | $55,276,834 |
| Diluted NI Availto Com Stockholders | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Other Special Charges | $2,737,000 | - | - | $4,483,000 |
| Research And Development | $20,282,000 | $20,589,000 | $15,440,000 | $13,584,000 |
| Selling General And Administration | $203,624,000 | $203,363,000 | $187,925,000 | $137,566,000 |
| Other Gand A | $62,744,000 | $55,720,000 | $47,031,000 | $32,999,000 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $67,392,000 | $92,002,000 | $116,098,000 | $60,529,000 |
| Total Assets | $190,581,000 | $217,094,000 | $251,907,000 | $159,024,000 |
| Total Non Current Assets | $58,527,000 | $55,692,000 | $53,548,000 | $25,622,000 |
| Other Non Current Assets | $1,221,000 | $407,000 | $146,000 | $146,000 |
| Goodwill And Other Intangible Assets | $19,940,000 | $20,890,000 | $21,840,000 | $0 |
| Other Intangible Assets | $7,125,000 | $8,075,000 | $9,025,000 | - |
| Current Assets | $132,054,000 | $161,402,000 | $198,359,000 | $133,402,000 |
| Other Current Assets | $5,501,000 | $5,667,000 | $7,853,000 | $3,624,000 |
| Inventory | $36,031,000 | $39,255,000 | $29,245,000 | $19,330,000 |
| Receivables | $42,155,000 | $40,803,000 | $38,063,000 | $29,196,000 |
| Accounts Receivable | $42,155,000 | $40,803,000 | $38,063,000 | $29,196,000 |
| Allowance For Doubtful Accounts Receivable | $-1,824,000 | $-1,326,000 | $-980,000 | $-735,000 |
| Gross Accounts Receivable | $43,979,000 | $42,129,000 | $39,043,000 | $29,931,000 |
| Cash Cash Equivalents And Short Term Investments | $48,367,000 | $75,677,000 | $123,198,000 | $81,252,000 |
| Cash And Cash Equivalents | $10,708,000 | $11,350,000 | $12,982,000 | $19,473,000 |
| Cash Equivalents | $7,836,000 | $5,995,000 | $3,160,000 | $16,211,000 |
| Cash Financial | $2,872,000 | $5,355,000 | $9,822,000 | $3,262,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $46,620,000 | $41,956,000 | $40,026,000 | $33,238,000 |
| Total Debt | $71,862,000 | $69,653,000 | $70,303,000 | $68,589,000 |
| Long Term Debt And Capital Lease Obligation | $69,565,000 | $69,240,000 | $68,899,000 | $68,250,000 |
| Long Term Debt | $55,583,000 | $53,306,000 | $53,008,000 | $52,711,000 |
| Current Debt And Capital Lease Obligation | $2,297,000 | $413,000 | $1,404,000 | $339,000 |
| Current Debt | $1,745,000 | - | - | - |
| Other Current Borrowings | $1,745,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $103,249,000 | $104,202,000 | $113,969,000 | $98,495,000 |
| Total Non Current Liabilities Net Minority Interest | $72,614,000 | $69,277,000 | $68,936,000 | $68,250,000 |
| Other Non Current Liabilities | $3,049,000 | $37,000 | $37,000 | - |
| Current Liabilities | $30,635,000 | $34,925,000 | $45,033,000 | $30,245,000 |
| Other Current Liabilities | $132,000 | $97,000 | $3,028,000 | - |
| Payables And Accrued Expenses | $21,875,000 | $25,715,000 | $29,712,000 | $22,240,000 |
| Interest Payable | $239,000 | $420,000 | $417,000 | $412,000 |
| Payables | $6,726,000 | $10,522,000 | $11,835,000 | $8,668,000 |
| Accounts Payable | $6,726,000 | $10,522,000 | $11,835,000 | $8,668,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $87,332,000 | $112,892,000 | $137,938,000 | $60,529,000 |
| Total Equity Gross Minority Interest | $87,332,000 | $112,892,000 | $137,938,000 | $60,529,000 |
| Stockholders Equity | $87,332,000 | $112,892,000 | $137,938,000 | $60,529,000 |
| Gains Losses Not Affecting Retained Earnings | $72,000 | $97,000 | $163,000 | $-27,000 |
| Other Equity Adjustments | $72,000 | $97,000 | $163,000 | $-27,000 |
| Retained Earnings | $-248,992,000 | $-189,990,000 | $-134,247,000 | $-84,720,000 |
| Other | ||||
| Treasury Shares Number | $165,513 | $23,391 | $1,218 | - |
| Ordinary Shares Number | $63,863,865 | $62,361,710 | $61,748,436 | $55,628,208 |
| Share Issued | $64,029,378 | $62,385,101 | $61,749,654 | $55,628,208 |
| Tangible Book Value | $67,392,000 | $92,002,000 | $116,098,000 | $60,529,000 |
| Invested Capital | $144,660,000 | $166,198,000 | $190,946,000 | $113,240,000 |
| Working Capital | $101,419,000 | $126,477,000 | $153,326,000 | $103,157,000 |
| Capital Lease Obligations | $14,534,000 | $16,347,000 | $17,295,000 | $15,878,000 |
| Total Capitalization | $142,915,000 | $166,198,000 | $190,946,000 | $113,240,000 |
| Treasury Stock | $1,183,000 | $281,000 | $13,000 | $0 |
| Additional Paid In Capital | $337,371,000 | $303,004,000 | $271,973,000 | $145,221,000 |
| Capital Stock | $64,000 | $62,000 | $62,000 | $55,000 |
| Common Stock | $64,000 | $62,000 | $62,000 | $55,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $13,982,000 | $15,934,000 | $15,891,000 | $15,539,000 |
| Current Capital Lease Obligation | $552,000 | $413,000 | $1,404,000 | $339,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,331,000 | $8,700,000 | $10,889,000 | $7,666,000 |
| Current Accrued Expenses | $15,149,000 | $15,193,000 | $17,877,000 | $13,572,000 |
| Goodwill | $12,815,000 | $12,815,000 | $12,815,000 | $0 |
| Net PPE | $37,366,000 | $34,395,000 | $31,562,000 | $25,476,000 |
| Accumulated Depreciation | $-23,869,000 | $-15,305,000 | $-8,748,000 | $-4,263,000 |
| Gross PPE | $61,235,000 | $49,700,000 | $40,310,000 | $29,739,000 |
| Leases | $10,591,000 | $10,244,000 | $9,425,000 | $6,434,000 |
| Construction In Progress | $1,069,000 | $612,000 | $1,115,000 | $705,000 |
| Other Properties | $40,761,000 | $31,111,000 | $23,517,000 | $19,386,000 |
| Machinery Furniture Equipment | $8,814,000 | $7,733,000 | $6,253,000 | $3,214,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $37,659,000 | $64,327,000 | $110,216,000 | $61,779,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,487,000 | $-48,760,000 | $-46,033,000 | $-45,486,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,970,000 | $-37,167,000 | $-34,575,000 | $-30,648,000 |
| Cash Flow From Continuing Operating Activities | $-15,970,000 | $-37,167,000 | $-34,575,000 | $-30,648,000 |
| Operating Gains Losses | $2,737,000 | - | - | $4,310,000 |
| Investing Activities | ||||
| Capital Expenditure | $-13,517,000 | $-11,593,000 | $-11,458,000 | $-14,838,000 |
| Investing Cash Flow | $13,251,000 | $35,375,000 | $-81,299,000 | $-76,518,000 |
| Cash Flow From Continuing Investing Activities | $13,251,000 | $35,375,000 | $-81,299,000 | $-76,518,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $107,527,000 | $0 |
| Financing Cash Flow | $2,077,000 | $160,000 | $109,383,000 | $20,806,000 |
| Cash Flow From Continuing Financing Activities | $2,077,000 | $160,000 | $109,383,000 | $20,806,000 |
| Net Other Financing Charges | $-1,464,000 | $-268,000 | $-13,000 | $-989,000 |
| Cash Dividends Paid | $0 | $0 | $0 | - |
| Net Common Stock Issuance | $0 | $0 | $107,527,000 | $0 |
| Common Stock Issuance | $0 | $0 | $107,527,000 | $0 |
| Other | ||||
| Issuance Of Debt | $59,310,000 | $0 | $0 | $53,501,000 |
| Interest Paid Supplemental Data | $4,997,000 | $4,955,000 | $5,167,000 | $4,398,000 |
| End Cash Position | $10,708,000 | $11,350,000 | $12,982,000 | $19,473,000 |
| Beginning Cash Position | $11,350,000 | $12,982,000 | $19,473,000 | $105,833,000 |
| Changes In Cash | $-642,000 | $-1,632,000 | $-6,491,000 | $-86,360,000 |
| Interest Paid Cff | $-56,315,000 | $0 | $0 | - |
| Proceeds From Stock Option Exercised | $546,000 | $428,000 | $1,869,000 | $2,187,000 |
| Net Issuance Payments Of Debt | $59,310,000 | $0 | $0 | $19,608,000 |
| Net Long Term Debt Issuance | $59,310,000 | $0 | $0 | $19,608,000 |
| Long Term Debt Issuance | $59,310,000 | $0 | $0 | $53,501,000 |
| Net Investment Purchase And Sale | $26,768,000 | $46,968,000 | $-49,841,000 | $-61,680,000 |
| Sale Of Investment | $67,339,000 | $118,547,000 | $120,024,000 | $1,729,000 |
| Purchase Of Investment | $-40,571,000 | $-71,579,000 | $-169,865,000 | $-63,409,000 |
| Net Business Purchase And Sale | $0 | $0 | $-20,000,000 | $0 |
| Purchase Of Business | $0 | $0 | $-20,000,000 | $0 |
| Net PPE Purchase And Sale | $-13,517,000 | $-11,593,000 | $-11,458,000 | $-14,838,000 |
| Purchase Of PPE | $-13,517,000 | $-11,593,000 | $-11,458,000 | $-14,838,000 |
| Change In Working Capital | $-8,584,000 | $-25,433,000 | $-9,743,000 | $-5,809,000 |
| Change In Other Working Capital | $35,000 | $97,000 | $40,000 | - |
| Change In Other Current Liabilities | $-3,207,000 | $-2,473,000 | $-119,000 | $3,076,000 |
| Change In Other Current Assets | $-503,000 | $-330,000 | $0 | $-146,000 |
| Change In Payables And Accrued Expense | $-6,209,000 | $-9,216,000 | $10,695,000 | $11,737,000 |
| Change In Accrued Expense | $-2,413,000 | $-7,903,000 | $7,528,000 | $7,125,000 |
| Change In Payable | $-3,796,000 | $-1,313,000 | $3,167,000 | $4,612,000 |
| Change In Account Payable | $-3,796,000 | $-1,313,000 | $3,167,000 | $4,612,000 |
| Change In Prepaid Assets | $166,000 | $2,186,000 | $-1,210,000 | $-668,000 |
| Change In Inventory | $3,224,000 | $-10,010,000 | $-9,848,000 | $-8,769,000 |
| Change In Receivables | $-2,090,000 | $-5,687,000 | $-9,301,000 | $-11,039,000 |
| Changes In Account Receivables | $-2,090,000 | $-5,687,000 | $-9,301,000 | $-11,039,000 |
| Other Non Cash Items | $3,722,000 | $3,185,000 | $2,963,000 | $2,791,000 |
| Stock Based Compensation | $33,823,000 | $30,603,000 | $17,352,000 | $8,111,000 |
| Provisionand Write Offof Assets | $834,000 | $2,947,000 | $434,000 | $411,000 |
| Amortization Of Securities | $-123,000 | $-1,145,000 | $-1,406,000 | $-126,000 |
| Depreciation Amortization Depletion | $10,623,000 | $8,419,000 | $5,352,000 | $2,133,000 |
| Depreciation And Amortization | $10,623,000 | $8,419,000 | $5,352,000 | $2,133,000 |
| Net Income From Continuing Operations | $-59,002,000 | $-55,743,000 | $-49,527,000 | $-42,815,000 |
| Repayment Of Debt | - | $0 | $0 | $-33,893,000 |
| Long Term Debt Payments | - | $0 | $0 | $-33,893,000 |
| Asset Impairment Charge | - | $0 | $0 | $346,000 |
| Gain Loss On Investment Securities | - | - | - | $-173,000 |
Fetched: 2026-06-17